Research programme: eye disorder therapeutics - Novartis/OctoPlus

Drug Profile

Research programme: eye disorder therapeutics - Novartis/OctoPlus

Latest Information Update: 13 Mar 2013

Price : $50

At a glance

  • Originator ESBATech
  • Developer Novartis; OctoPlus
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Eye disorders

Most Recent Events

  • 27 Feb 2013 OctoPlus has been acquired by Dr Reddys Laboratories
  • 17 Feb 2012 Preclinical trials in Eye disorders in Netherlands (Ophthalmic)
  • 01 Aug 2011 Early research is ongoing in Netherlands
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top